Biofrontera (BFRI) vs Lisata Therapeutics (LSTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Biofrontera (BFRI) has outperformed Lisata Therapeutics (LSTA) over the past year, losing 9.0% versus a loss of 52.6%. Biofrontera is the larger company by market cap ($13.6 million vs $13.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BFRI | LSTA |
|---|---|---|
| Share price | $0.9188 | $1.20 |
| Market cap | $13.65M | $12.96M |
| 1-day change | -1.77% | +2.56% |
| YTD return | +61.19% | -35.48% |
| 1-year return | -9.03% | -52.57% |
| 5-year return | — | -93.44% |
| Forward P/E | 2.14 | — |
| EPS (TTM) | $-0.43 | $-1.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.66 | $5.07 |
| 52-week low | $0.555 | $0.99 |
| Distance from 52-week high | -44.65% | -76.33% |
| Analyst consensus | none | none |
| Avg. price target upside | +553.03% | — |
| Average volume | 547.45K | 291.91K |
| Shares outstanding | 14.85M | 10.80M |
| Employees | 84 | 21 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BFRI has outperformed LSTA by 43.5 percentage points over the past year.
About Biofrontera
BFRI stock →Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Healthcare · Drug Manufacturers - Specialty & Generic · 84 employees
About Lisata Therapeutics
LSTA stock →Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.
Healthcare · Biotechnology · 21 employees
BFRI vs LSTA FAQ
Which is bigger, Biofrontera or Lisata Therapeutics?
Biofrontera (BFRI) is larger, with a market capitalization of $13.65M compared with $12.96M for Lisata Therapeutics (LSTA).
Which stock has performed better over the past year, BFRI or LSTA?
BFRI returned -9.03% over the past 12 months, compared with -52.57% for LSTA (price return, excluding dividends). Past performance does not predict future results.
Are Biofrontera and Lisata Therapeutics in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Biofrontera and Biotechnology for Lisata Therapeutics.